What is Moravek?
Moravek, Inc. is a distinguished entity in the life sciences sector, specializing in the production of high-quality radiolabeled and stable-labeled compounds. Their core expertise lies in GMP carbon-14 labeled active pharmaceutical ingredients (APIs), essential for early-phase clinical trials. With an operational history spanning over 45 years, Moravek offers comprehensive custom synthesis, purification, and analytical services tailored to the needs of global pharmaceutical companies and research institutions. The company's extensive catalog of isotopically labeled compounds, coupled with a rigorous quality system, ensures adherence to stringent regulatory standards, solidifying its reputation for reliability and client-centric solutions in pharmaceutical research and development.
How much funding has Moravek raised?
Moravek has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
What's next for Moravek?
The recent large-scale late-stage funding and major strategic investment signal a period of accelerated growth and potential expansion for Moravek. This capital infusion is likely to bolster their manufacturing capabilities, research and development initiatives, and market reach within the pharmaceutical and biotechnology sectors. The company's focus on GMP-compliant APIs for clinical trials positions it to capitalize on the increasing demand for specialized chemical synthesis services, potentially leading to new partnerships and advancements in drug discovery and development.
See full Moravek company page
